Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Barasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB known ✓ | Q96GD4 | 13/20 | 1.00 |
| ▸ | AURKA | O14965 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | HCK | P08631 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | MST1R | Q04912 | 2/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 1.00 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | RAB6A | P20340 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Barasertib SCHEMBL29720420 | 1.00 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| Barasertib SCHEMBL29368256 | 1.00 | AURKA (1.00) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3490131 | 0.98 | AURKA (0.96) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL4275319 | 0.97 | AURKA (0.94) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3489414 | 0.96 | AURKA (0.93) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL12132713 | 0.95 | AURKA (0.92) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL613581 | 0.95 | AURKA (0.91) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3862878 | 0.95 | AURKA (0.90) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL3489712 | 0.95 | AURKA (0.90) | AURKAAURKBEGFRKDRRIPK2 | |
| SCHEMBL12132714 | 0.95 | AURKA (0.90) | AURKAAURKBEGFRKDRRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022144780-A1 | SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS | NATIONAL CANCER CENTER (JP) | 2022-07-07 | — | — | WO | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2020-06-11 | — | — | US | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| EP-2788504-B1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY OLOMOUC (CZ) | 2016-08-17 | — | — | EP | claimed |
| US-20140336073-A1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2014-11-13 | — | — | US | claimed |
| EP-2788504-A2 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | Palacky University, Olomouc (CZ) | 2014-10-15 | — | — | EP | claimed |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2014-06-12 | — | — | US | claimed |
| WO-2013083098-A2 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2013-06-13 | — | — | WO | claimed |
| EP-2602330-A1 | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance | Palacky University, Olomouc (CZ) | 2013-06-12 | — | — | EP | claimed |
| JP-2011506420-A | — | — | 2011-03-03 | — | — | JP | claimed |
| EP-2231281-A2 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20100004247-A1 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | US | claimed |
| US-7625910-B2 | Co-crystal | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | claimed |
| US-20090253616-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | claimed |
| WO-2009074827-A2 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | claimed |
| US-7528121-B2 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2009-05-05 | — | — | US | claimed |
| EP-1578755-B1 | PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | EP | claimed |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181284-A1 | EPIGENETIC INHIBITORS FOR SENSITIZING HEMATOLOGIC OR OTHER MALIGNANCIES TO GLUCOCORTICOID THERAPY | NR3C1, EZH2, MECP2 | AURKB 707/4885AURKA 1971/4885EGFR 3808/4885 |
| US-20140162984-A1 | PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | PLK2, ABL1, CYP3A5 | AURKB 575/4885AURKA 220/4885EGFR 2101/4885 |
| US-20090253616-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | AURKC, AURKB, AURKA | AURKB 2/4885AURKA 3/4885EGFR 274/4885 |
| US-20060116357-A1 | Aurora kinases inhibitors; antiproliferative agents; specially for solid and haematological tumors; 2-[[3-({4-[(5-{2-[(3-fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate | AURKA, AURKC, AURKB | AURKB 3/4885AURKA 1/4885EGFR 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.